Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of ENDRA Life Sciences Inc (NASDAQ: NDRA) was $6.23 for the day, up 17.11% from the previous closing price of $5.32. In other words, the price has increased by $17.11 from its previous closing price. On the day, 0.12 million shares were traded. NDRA stock price reached its highest trading level at $6.2797 during the session, while it also had its lowest trading level at $5.15.
Ratios:
Our analysis of NDRA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.31 and its Current Ratio is at 1.31. In the meantime, Its Debt-to-Equity ratio is 3.12 whereas as Long-Term Debt/Eq ratio is at 2.35.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NDRA now has a Market Capitalization of 9326902 and an Enterprise Value of 6998219.
Stock Price History:
The Beta on a monthly basis for NDRA is -0.32, which has changed by -0.0683012 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, NDRA has reached a high of $11.96, while it has fallen to a 52-week low of $2.90. The 50-Day Moving Average of the stock is 8.83%, while the 200-Day Moving Average is calculated to be 30.73%.
Shares Statistics:
NDRA traded an average of 278.63K shares per day over the past three months and 87110 shares per day over the past ten days. A total of 1.17M shares are outstanding, with a floating share count of 0.90M. Insiders hold about 22.55% of the company’s shares, while institutions hold 1.12% stake in the company. Shares short for NDRA as of 1763078400 were 100283 with a Short Ratio of 0.36, compared to 1760486400 on 96975. Therefore, it implies a Short% of Shares Outstanding of 100283 and a Short% of Float of 9.15.
Earnings Estimates
The stock of ENDRA Life Sciences Inc (NDRA) is currently being evaluated by 1.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$2.46, with high estimates of -$2.46 and low estimates of -$2.46.
Analysts are recommending an EPS of between -$7.48 and -$7.48 for the fiscal current year, implying an average EPS of -$7.48. EPS for the following year is -$8.89, with 1.0 analysts recommending between -$8.89 and -$8.89.
Revenue Estimates
Based on 1 analysts’ estimates, the company’s revenue will be $300k in the next fiscal year. The high estimate is $300k and the low estimate is $300k.
